---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-099645"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:30:53.964117+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Oruka shareholders approve Series A conversion and adjournment proposals

## Summary
- 30,598,476 shares voted for Series A conversion; 6,026 against; 1,089 abstaining; no broker non-votes.
- 29,294,720 shares voted for adjournment proposal; 1,309,805 against; 1,066 abstaining.
- Both proposals approved at special meeting held November 14, 2024.
- Conversion involves Series A Non-Voting Convertible Preferred Stock issued September 2024.

## SEC filing metadata
- accession: 0001213900-24-099645
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024099645/0001213900-24-099645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024099645/ea0221692-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-099645
- JSON: https://secwatch.observer/filing/0001213900-24-099645.json
- Plain text: https://secwatch.observer/filing/0001213900-24-099645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.